Minocycline

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Minocycline
Category Antibiotics
Catalog number BBF-03789
CAS 10118-90-8
Molecular Weight 457.48
Molecular Formula C23H27N3O7
Purity 95%

Online Inquiry

Description

Minocycline is a broad-spectrum tetracycline antibiotic, which has a broader spectrum than the other members of the group. It is effective against tetracycline-resistant staphylococcus infections. It is a bacteriostatic antibiotic and is classified as a long-acting type. It is the most lipid-soluble of the tetracycline-class antibiotics, giving it the greatest penetration into the prostate and brain. It is not a naturally-occurring antibiotic, but was synthesized semi-synthetically from natural tetracycline antibiotics by Lederle Laboratories in 1966. It is mainly used for the treatment of acne and other skin infections. Its application is very limited because of its side effects.

Specification

Related CAS 13614-98-7 (hydrochloride)
Synonyms Minostad; Akamin; Minocin; Minoderm; Cyclimycin; Solodyn; Dynacin; Sebomin; Divaine; Tigecycline EP Impurity C
Shelf Life 2 month in rt, long time
Storage Store at -20°C (dark)
IUPAC Name (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
Canonical SMILES CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C
InChI InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27-28,31,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
InChI Key FFTVPQUHLQBXQZ-KVUCHLLUSA-N
Source Semi-synthetic

Properties

Appearance Orange Solid
Antibiotic Activity Spectrum bacteria
Boiling Point 659.401°C at 760 mmHg
Density 1.553 g/cm3
Solubility Soluble in DMSO

Reference Reading

1.Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia.
Giovanoli S1,2, Engler H3, Engler A3, Richetto J4,5,6, Feldon J2, Riva MA4,5, Schedlowski M3, Meyer U1,2,6. Transl Psychiatry. 2016 Apr 5;6:e772. doi: 10.1038/tp.2016.38.
Maternal immune activation can increase the vulnerability of the offspring to develop neuroimmune and behavioral abnormalities in response to stress in puberty. In offspring of immune-challenged mothers, stress-induced inflammatory processes precede the adult onset of multiple behavioral dysfunctions. Here, we explored whether an early anti-inflammatory intervention during peripubertal stress exposure might prevent the subsequent emergence of adult behavioral pathology. We used an environmental two-hit model in mice, in which prenatal maternal administration of the viral mimetic poly(I:C) served as the first hit, and exposure to sub-chronic unpredictable stress during peripubertal maturation as the second hit. Using this model, we examined the effectiveness of the tetracycline antibiotic minocycline (MINO) given during stress exposure to block stress-induced inflammatory responses and to prevent subsequent behavioral abnormalities. We found that combined exposure to prenatal immune activation and peripubertal stress caused significant deficits in prepulse inhibition and increased sensitivity to the psychotomimetic drugs amphetamine and dizocilpine in adulthood.
2.Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
Song Z1, Suo B1, Zhang L1, Zhou L1. Helicobacter. 2016 Apr 6. doi: 10.1111/hel.12313. [Epub ahead of print]
BACKGROUND: Because of general unavailability of tetracycline, common adverse effects, and complicated administration, the clinical application of bismuth quadruple therapy often faces difficulties. Whether the combination of minocycline and amoxicillin can replace tetracycline and metronidazole for Helicobacter pylori eradication remains unclear. This study was to determine the efficacy, compliance, and safety of rabeprazole, minocycline, amoxicillin, and bismuth (RMAB) therapy as first-line and second-line regimens.
3.Empirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach.
VanEperen AS1, Segreti J2. J Infect Chemother. 2016 Apr 8. pii: S1341-321X(16)30009-5. doi: 10.1016/j.jiac.2016.02.012. [Epub ahead of print]
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be an important pathogen worldwide, with high prevalence of infection in both community and hospital settings. Timely and appropriate choice of empirical therapy in the setting of MRSA infection is imperative due to the high rate of associated morbidity and mortality with MRSA infections. Initial choices should be made based on the site and severity of the infection, most notably moderate skin and soft tissue infections which may be treated with oral antibiotics (trimethoprim-sulfamethoxazole, clindamycin, doxycycline/minocycline, linezolid) in the outpatient setting, versus choice of parenteral therapy in the inpatient setting of more invasive or severe disease. Though the current recommendations continue to strongly rely on vancomycin as a standard empiric choice in the setting of severe/invasive infections, alternative therapies exist with studies supporting their non-inferiority.
4.Severe and Persistent Thyroid Dysfunction Associated with Tetracycline-Antibiotic Treatment in Youth.
Pollock AJ1, Seibert T2, Allen DB3. J Pediatr. 2016 Apr 5. pii: S0022-3476(16)00415-7. doi: 10.1016/j.jpeds.2016.03.034. [Epub ahead of print]
Thyroid dysfunction in adolescents treated with minocycline for acne has been previously described as transient effect and/or associated with autoimmune thyroiditis. We report nonimmune-mediated thyroid dysfunction associated with minocycline/doxycycline in 3 adolescents whose clinical courses suggest an adverse effect that may be more common, serious, and persistent than realized previously.

Recommended Products

BBF-05818 Docosahexaenoic acid Inquiry
BBF-05817 Astaxanthin Inquiry
BBF-03211 AT-265 Inquiry
BBF-05781 Emodepside Inquiry
BBF-00664 Alternariol Inquiry
BBF-03753 Baicalin Inquiry

Bio Calculators

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Recently viewed products

Online Inquiry

Verification code

Copyright © 2024 BOC Sciences. All rights reserved.

cartIcon
Inquiry Basket